Medical/Pharmaceuticals

Elekta establishes a framework for sustainability-linked bonds

STOCKHOLM, Oct. 29, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has established a Sustainability-Linked Bond Framework (SLB Framework) for issues of sustainability-linked bonds under itsMedium Term Note Program  (MTN-Program). Elekta is among the first companies inSweden to est...

2021-10-29 15:29 3377

Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC

SUZHOU, China, Oct. 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, a pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 inChina (ENREACH-LUNG-02) recently completed the first drug administration. ENREACH-LUNG-02 is a multi-center, open-label, randomized...

2021-10-29 09:36 3136

Hanmi Science Consortium Drives Ambitious Project for Worldwide Vaccine Equity

SEOUL, South Korea, Oct. 29, 2021 /PRNewswire/ -- Hanmi Science doesn't just want the world to know they are committed to vaccine equity, they want to prove it. Mr. Lim, CEO of Hanmi Science, echoes the concerns of Mr.Bill Gates, co-founder of the Bill & Melinda Gates Foundation. As Mr. Gates sta...

2021-10-29 09:27 3285

World Stroke Day: Global survey reveals only 35% hospitals worldwide provide essential stroke treatment

GENEVA, Oct. 29, 2021 /PRNewswire/ -- On World Stroke Day, 29 October, the World Stroke Organization (WSO) is calling for urgent action after a survey by the WSO and the World Health Organization (WHO) found that only 35% of hospitals worldwide provide essential clot-busting medicine tissue plasm...

2021-10-29 06:01 2052

ImmunoForge Inc. receives U.S. FDA ODD for PF1801

SEOUL, South Korea and SILVER SPRING, Md., Oct. 29, 2021 /PRNewswire/ -- ImmunoForge (Co-CEOsSung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 which is in development for treatment of D...

2021-10-29 05:50 4333

EZZ Marks Transition to Genomic Health Following Exceptional FY21 Performance

About EZZ Life Science Holdings EZZ Life Science Holding Limited (ASX:EZZ) is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papi...

2021-10-29 04:05 4583

FII Institute Announces Investment in AZmed, Helping to Address Global Shortage in Radiologists

RIYADH, Saudi Arabia, Oct. 28, 2021 /PRNewswire/ -- The Future Investment Initiative (FII) Institute has announced a1 million EUR investment in AZmed, developers of Artificial Intelligence-enabled diagnostic applications which can help address the shortage of radiologists around the world.

2021-10-28 23:15 4323

Merck Drives New Innovation & Adds Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies

- Merck's unique technology, ChetoSensar™, gives new promise to ADCs by alleviating solubility challenges  - New DOLCORE™ platform increases speed-to-market by up to a year - Expanded ADC clinical manufacturing facility drives next generation ADCs, building on company's 15 years of ADC Contract...

2021-10-28 21:00 4228

BioVaxys Further Expands Intellectual Property Portfolio in Global Markets

- Files Applications for International Patent and Trademark Protection of CoviDTH VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has broadened the patent coverage on CoviDTH, its T ...

2021-10-28 20:00 3944

Interim report for Q3 2021 : Bactiguard Holding AB (publ)

STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Capital injection initiates a new phase of accelerated expansion Third quarter (July-September 2021) * Revenues amounted to SEK 45.2 (34.1) million, an increase of 32%. Adjusted for currency effects revenues increased by 36%. * EBITDA amounted to SEK ...

2021-10-28 15:23 2359

Mentice publishes the company's interim report for the period January-September 2021

STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Third quarter (July–September 2021) and the first nine months of the year (January-September 2021) * Order intake amounted to 51.8 (34.6) MSEK for the third quarter and 131.9 (95.5) MSEK for the first nine months of the year. * Order book by the end ...

2021-10-28 15:07 1990

Innovent and NeoCura Announce Strategic Collaboration to Study the Combination Therapy of Sintilimab and Neoantigen Vaccine NEO_PLIN2101 for Cancer Treatment in China

SAN FRANCISCO and SUZHOU, China, Oct. 28, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-10-28 08:00 4014

Ingersoll Rand and its Brands Support the Public Health in the Post-Pandemic Era

SINGAPORE, Oct. 27, 2021 /PRNewswire/ -- Ingersoll Rand Inc. (NYSE:IR), a global provider of mission-critical flow creation and industrial solutions, is providing compressed air and vacuum, material handling, and metering solutions to the medical and pharmaceutical industries. Its cutting-edge co...

2021-10-28 05:47 4166

New Wellbeing Trends Report 2030 Reveals Decade-long Impact of Pandemic Upheaval

SYDNEYOct. 28, 2021 /PRNewswire/ -- Jeunesse Global today shared the inaugural Wellness & Aesthetics Trends Report 2030, presenting key macro and micro trends that are set to influence the future of the wellbeing and beauty sectors, based on the evolution of audience behaviours and cultural shift...

2021-10-28 03:54 2700

Launch of Seegene's STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing

* A true walk away 'sample to answer' molecular diagnostic system designed for high throughput testing, offering a time-efficient and seamless workflow for clinical laboratories * Utilizes Seegene's patented, cutting-edge high multiplex real-time PCR technologies to provide 'Real' Ct values...

2021-10-27 23:40 2920

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 22:08 2010

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 22:06 1744

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 22:03 1899

Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore

- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium - - ADG106 now being evaluated in combinations with three leading anti-PD-1 therapies - SAN DIEG...

2021-10-27 20:52 4626

Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom

* Filing marks first protein-based COVID-19 vaccine submitted to MHRA for authorization * All modules required for regulatory review, including CMC data, are now complete * Submission based on Phase 3 data from ~45K patients demonstrating high efficacy and well-tolerated safety, including a...

2021-10-27 20:30 4092
1 ... 369370371372373374375 ... 382